Avidity Biosciences, Inc. | LinkedIn (original) (raw)

About us

DELIVERING ON OUR VISION Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide-based therapies in order to redefine RNA therapeutics and more effectively target underlying genetic drivers of diseases. We are delivering on this vision by investing in our platform, our pipeline and our people. Through this platform, we are pleased to share our ideas and company progress as we advance our science and overall mission to deliver breakthrough therapies to patients.

Industry

Biotechnology

Company size

51-200 employees

Headquarters

San Diego, California

Type

Public Company

Specialties

drug discovery and development, nucleic acids, RNA, and rare disease

Locations

Employees at Avidity Biosciences, Inc.

Updates

19,121 followers
2d Edited
Meet Loraine: nurse, advocate, and caregiver navigating life with myotonic dystrophy type 1 (#DM1). When her daughter, grandson, and she were diagnosed with DM1, she channeled her nursing experience into creating comprehensive care plans and advocating for her family while managing her own symptoms. As they navigate the complexities of DM1, Loraine highlights the importance of finding a physician who will take the time to listen and learn about each individual’s own challenges with the disease. Beyond caregiving, Loraine has also led support groups and advocated for better understanding of DM1's impact on families. This #NationalFamilyCaregiversMonth, we honor dedicated caregivers like Loraine who transform challenges into advocacy and hope. Read their story: https://lnkd.in/eHXYw38U #NFCM2024
19,121 followers
3d Edited
During the American Heart Association Scientific Sessions in Chicago, Georgios Karamanlidis, PhD, EMBA, our Senior Director of Precision Cardiology, will deliver a poster presentation sharing how we are expanding the reach of our Antibody-Oligonucleotide Conjugates (AOCs™) into other indications such as #cardiology. Learn more about our lead precision cardiology candidates and next-generation therapeutic innovations for the broader AOC platform: https://lnkd.in/eZ2q7ukX
We are excited to share that Avidity is opening up a new therapeutic field, precision cardiology, to address the root cause of genetic diseases of the heart. Today at 8:00am ET, our management team will be hosting an investor & analyst event highlighting two new wholly-owned precision cardiology development candidates targeting rare genetic cardiomyopathies as well as a first-look at preclinical data from our next-generation technology innovations. Visit our website to register for the event: https://lnkd.in/eZ2q7ukXThis marks a significant milestone for Avidity as we leverage the broad utility of our proprietary AOC platform to address the underlying cause of genetic heart diseases in precision cardiology. For more information read our press release: https://lnkd.in/eyVDJNmV
Our Associate Director of IT, R&D Systems, Cindy Novak - DeLaurell, will be sharing insights from Avidity's #AI journey at AMG World’s Future Labs, Automation, & Technology conference on November 12. We’re excited for the opportunity to share insights on leveraging AI to drive innovation at Avidity and within the #lifesciences industry. Learn more about Avidity and our innovative AOC pipeline for people and their families impacted by serious rare diseases: https://lnkd.in/dH-56XKM #FutureLabsWest
Join us this November in celebrating #NationalFamilyCaregiversMonth. As the backbone of the #raredisease community, caregivers work tirelessly to advocate for those they care about as well as advancements in research and care. We want to recognize their time, commitment, and continued contributions. At Avidity, we are committed to listening, learning, and partnering with patients and caregivers as we remain steadfast in our commitment to advance meaningful therapies for the muscular dystrophy community. Read these powerful stories of strength and dedication:https://lnkd.in/eaHk-mpS #NFCMonth #NFCM #FamilyCaregivers #Caregiving
We're excited to share that we have initiated a biomarker cohort in our Phase 1/2 FORTITUDE™ clinical trial for people living with facioscapulohumeral muscular dystrophy (#FSHD). The initiation of the biomarker cohort marks a key step in our strategy to pursue a potential accelerated approval path for the first potential treatment to directly target the root cause of FSHD. Currently, there are no approved therapies for the treatment of FSHD, a rare, hereditary disorder marked by life-long, relentless loss of muscle function, significant pain, fatigue, and progressive disability. The community's response and interest in the FORTITUDE study has been tremendous. We are grateful for their partnership and understand the urgency to bring a new treatment to people living with FSHD as quickly as possible. For more information, see our press release: https://lnkd.in/eTmGDgkF
At Avidity, we are driven by our mission to profoundly improve people’s lives by revolutionizing a new class of targeted RNA therapeutics. We are proud to have a team of dynamic and dedicated individuals who are committed to providing new and innovative treatment options for patients and their families. If you’re eager to make a real difference and thrive in a culture that values both professional excellence and personal well-being, Avidity is the place for you. Join us and be part of a team where your contributions fuel innovation and impact lives. Explore our available opportunities: https://lnkd.in/dWCgkwVY #BeAVID
Last week our Chief Program Officer, Kathleen Gallagher, participated in the first FDA Rare Disease Innovation Hub meeting held in collaboration with the Reagan-Udall Foundation for the FDA. The meeting brought together patient advocates, academic researchers, industry members and other key stakeholders to discuss how to best engage with members of the #raredisease community and support rare disease related policies and initiatives. Over 30 million people in the U.S. are affected by rare diseases and many lack effective treatments. The work of the Rare Disease Innovation Hub is crucial in driving progress for these patients. At Avidity, we value the importance of a shared vision as we advance our clinical development programs for #DM1, #FSHD, and #DMD44, working toward bringing much-needed therapies to those living with these devastating rare diseases. Learn more about the Rare Disease Innovation Hub at https://lnkd.in/epxcdyZk and learn more about our ongoing commitment to the #raredisease community at https://lnkd.in/dH-56XKM
We are proud to support the 18th International Congress on Neuromuscular Diseases (ICNMD), organized by the Specialty Group on Neuromuscular Diseases (NMD) of the World Federation Of Neurology (WFN) in Perth, Australia. We look forward to engaging with the global neuromuscular community, gaining the latest insights into neuromuscular disorders, and fostering valuable networking opportunities and international collaborations. Our team will be on-site to connect with industry leaders and innovators who share our commitment to making a meaningful impact in the lives of individuals with muscular diseases. Learn more about the conference: https://icnmd.org/ #ICNMD24

Join now to see what you are missing

Join now

Avidity Biosciences, Inc. | LinkedIn (original) (raw)

About us

Locations

Employees at Avidity Biosciences, Inc.

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding